Stryka 425
Alternative Names: Stryka-425Latest Information Update: 25 Sep 2020
At a glance
- Originator University of Nevada Reno
- Developer Strykagen
- Class Small molecules
- Mechanism of Action Integrin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Duchenne muscular dystrophy; Limb girdle muscular dystrophies; Muscular dystrophies
Most Recent Events
- 25 Sep 2020 Stryka 425 is available for licensing as of 25 Sep 2020. www.strykagen.com